Clinical trial · Observational
Enabling the Study of Metabolism in Breast Cancer Through Collection of Fresh-tissue Biopsies
NCT03880097CI-TRIAL-00037686ENSEMBLEnot yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to evaluate how breast cancer cells metabolise nutrients in order to grow. Patients enrolled into this study will undergo a research biopsy that will aim to collect up to 4 cores of tumour tissue. These tissues will then be used in translational research to analyse how specific pro-tumorigenic events change breast cancer cell metabolism (compared to healthy cell metabolism).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Research Biopsy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Research Biopsy
- description
- The research biopsy is the same procedure as a standard of care percutaneous biopsy. A "core" (hollow) needle is inserted into the tumour tissue in order to collect tissue samples. The procedure is called a research biopsy as it is an additional procedure to the standard of care, used purely to collect tissue samples for research purposes.
- interventionNames
- Procedure: Research Biopsy
Primary outcomes (1)
- measure
- Number of biopsies collected
- timeFrame
- 3 years
- description
- The primary outcome is the number of biopsies successfully collected from the 240 women approached.
Secondary outcomes (2)
- measure
- Breast cancer cell biology
- timeFrame
- 5 years
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histological diagnosis of newly diagnosed breast cancer * Known ER and HER2 receptor status * Tumour diameter ≥1cm on imaging * Female * Age 18 or above * Written informed consent Exclusion Criteria: * Previously treated invasive breast cancer * Primary systemic therapy for breast cancer prior to biopsy * Oestrogen replacement therapy (HRT) within 14 days of biopsy in ER-positive tumours * Pregnancy or breastfeeding * Not considered suitable by clinical team
References
Publications (0)
Data not yet available
No reference posted for this study.